AOD-9604 vs Tirzepatide.
Quick Verdict
AOD-9604 is a gh fragment primarily researched for fat loss without gh side effects, while Tirzepatide is a dual agonist (glp-1/gip) studied for weight loss, body recomposition, glycemic control. A key distinction: Tirzepatide has FDA approval status.
Side-by-Side Analysis
| Dimension | AOD-9604 | Tirzepatide |
|---|---|---|
| Category | GH Fragment | Dual Agonist (GLP-1/GIP) |
| Mechanism | Mimics GH fat-burning domain. | Dual receptor agonism at GLP-1 and GIP receptors for synergistic appetite suppression, improved insulin sensitivity, and enhanced metabolic function. |
| Half-Life | ~1 hours | ~5 days |
| Route | SubQ | SubQ |
| Typical Dose | 300–300 mcg | 2500–2500 mcg |
| Frequency | 7x/wk | 1x/wk |
| Evidence Level | Preclinical | Very Strong |
| Indexed Studies | 18+ indexed | 20+ indexed |
| FDA Status | Research Only | Approved |
| Lowest Price | $49.99 / 5mg via Amino Club | $69.99 / 5mg via Amino Club |
| Per-mg Cost | $10.00/mg | $14.00/mg |
Mechanism of Action Comparison
How AOD-9604 Works
AOD-9604 AOD-9604 is a synthetic fragment of human growth hormone studied for its ability to burn fat without the blood sugar or growth side effects of full GH.
Mimics GH fat-burning domain. Stimulates lipolysis and inhibits lipogenesis by acting on beta-3 adrenergic receptors in fat tissue, without binding to the GH receptor.
How Tirzepatide Works
Tirzepatide Tirzepatide is an FDA-approved dual GLP-1/GIP agonist sold as Mounjaro for type 2 diabetes and Zepbound for obesity, achieving up to 22.5% body weight loss in clinical trials.
Dual receptor agonism at GLP-1 and GIP receptors for synergistic appetite suppression, improved insulin sensitivity, and enhanced metabolic function.
Key Mechanistic Difference
AOD-9604 operates as a gh fragment, while Tirzepatide functions as a dual agonist (glp-1/gip) — these are fundamentally different pharmacological approaches. Tirzepatide has a significantly longer half-life (~5 days) compared to AOD-9604 (~1 hours), which impacts dosing frequency and sustained activity.
Research Evidence
AOD-9604
18 studies- AOD-9604 lipolysis stimulation in preclinical modelsNg et al. demonstrate AOD-9604 stimulates lipolysis and inhibits lipogenesis in adipose tissue without affecting IGF-1 o…Preclinical
- AOD-9604 clinical safety six randomized controlled trialsHeffernan et al.: Pooled analysis of 6 RCTs showing AOD-9604 is well-tolerated with a safety profile similar to placebo …Moderate
- AOD-9604 Phase IIb trial short-term fat reduction12-week Phase IIb trial: 1mg/day AOD-9604 produced 2.6 kg weight loss vs 0.8 kg placebo, with reductions in abdominal fa…Moderate
Tirzepatide
20 studies- Tirzepatide Phase 3 SURMOUNT-1: up to 22.5% weight lossJastreboff et al. (NEJM): Phase 3 SURMOUNT-1 trial tirzepatide 15mg achieved 22.5% body weight reduction vs 2.4% place…Very Strong
- SURMOUNT-4: 176-week long-term weight maintenanceAronne et al.: 176-week data showing sustained weight loss maintenance with continued tirzepatide treatment 15mg dose …Very Strong
- Tirzepatide meta-analysis: BMI, weight, and metabolic outcomesMeta-analysis of multiple RCTs confirming tirzepatide significantly reduces BMI, waist circumference, body weight, and H…Very Strong
Vendor Pricing
· Affiliate links · Prices verified 2026AOD-9604
2 vendorsTirzepatide
2 vendorsAffiliate disclosure: PeptiDex may earn a commission from purchases via vendor links at no extra cost to you. See our methodology.
Frequently Asked Questions
Can I take AOD-9604 and Tirzepatide together?▼
No direct interaction data is available for this specific pair. They target different receptor systems, suggesting they could potentially be combined, but no published protocol validates this combination.
Which has more research evidence — AOD-9604 or Tirzepatide?▼
AOD-9604 has 18 indexed studies (highest evidence: Preclinical). Tirzepatide has 20 indexed studies (highest evidence: Very Strong). Tirzepatide has a more extensive research base.
What is the price difference between AOD-9604 and Tirzepatide?▼
At current verified vendor prices, AOD-9604 starts at $10.00/mg while Tirzepatide starts at $14.00/mg. Prices vary by vendor and vial size — see the full vendor comparison below.
Which is better for fat loss — AOD-9604 or Tirzepatide?▼
Both are researched for fat loss. AOD-9604 addresses this via fat loss without gh side effects. Tirzepatide approaches it through weight loss, body recomposition, glycemic control. The optimal choice depends on your specific research protocol and which mechanism aligns with your objectives.
Is AOD-9604 or Tirzepatide FDA-approved?▼
Tirzepatide has FDA approval (or is derived from an FDA-approved compound). AOD-9604 is a research compound without FDA approval for human use. FDA status reflects regulatory evaluation — not necessarily superiority for all research applications.
Related Comparisons
Deep Dive Profiles
Shared Research Goals
Research Use Only — Not Medical Advice
This comparison is provided for educational and research purposes only. It does not constitute medical, prescribing, or treatment advice. Clinical data cited here is sourced from published peer-reviewed trials and FDA labels. Consult a qualified healthcare professional before making any decisions about medications or research compounds. PeptiDex is an informational resource and does not sell pharmaceutical products.